Skip to main content

Table 2 Characteristics of subjects stratified by gender and the presence/absence of metabolic syndrome

From: Association of metabolic syndrome and its components with arterial stiffness in Caucasian subjects of the MARK study: a cross-sectional trial

Variables

Males subjects (n = 1450)

Females subjects (n = 901)

MetS + n = 667

MetS − n = 783

MetS + n = 553

MetS − n = 348

Age, (years)*

60.5 ± 8.1

61.8 ± 8.1

61.7 ± 7.1

62.1 ± 6.9

SBP, (mmHg)*†

141.4 ± 16.1

136.7 ± 17.5

136.3 ± 17.1

130.6 ± 17.7

DBP. (mmHg)*†

87.5 ± 10.3

83.7 ± 10.1

83.5 ± 9.2

81.2 ± 10.2

Hypertension, n (%)*†

600 (90.0)

563 (71.9)

469 (84.8)

210 (60.3)

Antihypertensive drugs, n (%)*†

404 (60.6)

329 (42.0)

352 (63.7)

123 (35.3)

HDL-C, (mg/dl)*†

43.2 ± 10.3

51.9 ± 11.8

48.3 ± 11.2

60.3 ± 14.2

TGC, (mg/dl)*†

184.0 ± 132.4

116.8 ± 54.0

160.8 ± 87.9

101.8 ± 37.5

Dyslipidemia, n (%)

436 (65.4)

488 (62.3)

403 (72.9)

256 (73.6)

Lipid lowering drugs, n (%)*†

207 (31.0)

185 (23.6)

197 (35.6)

84 (24.1)

FPG (mg/dl)*†

118.6 ± 37.9

98.0 ± 25.8

118.2 ± 39.3

91.8 ± 21.3

Diabetes mellitus type 2, n (%)*†

329 (49.3)

135 (17.2)

289 (52.3)

41 (11.8)

Antidiabetic drugs, n (%)*†

198 (29.7)

72 (9.2)

188 (34.0)

19 (5.5)

WC, (cm)*†

108.3 ± 10.1

98.3 ± 8.5

101.5 ± 11.3

91.4 ± 11.6

Higher blood pressure, n (%)*†

644 (96.6)

609 (77.8)

512 (92.6)

221 (63.5)

Higher FPG, n (%)*†

494 (74.1)

199 (25.4)

378 (68.4)

41 (11.8)

Lower HDL-C, n (%)*†

295 (44.2)

62 (7.9)

372 (67.3)

62 (17.8)

Higher TGC, n (%)*†

423 (63.4)

122 (15.6)

269 (48.6)

25 (7.2)

Higher WC, n (%)*†

539 (80.8)

223 (28.5)

516 (93.3)

200 (57.5)

CAVI

8.86 ± 1.24

8.94 ± 1.14

8.66 ± 1.19

8.61 ± 1.01

CAVI ≥ 9, n (%)

319 (49.3)

382 (49.9)

230 (42.8)

130 (38.9)

baPWV, (m/s)*†

14.98 ± 2.50

14.66 ± 2.61

15.23 ± 2.59

14.60 ± 2.36

baPWV ≥ 17.5 m/s, n (%)

94 (14.1)

98 (12.5)

97 (17.5)

35 (10.1)

  1. Values are means (standard deviations (SD) for continuous data and number and proportions for categorical data
  2. Metabolic syndrome: Three or more of the following criteria: (abdominal obesity = higher WC: waist circumference ≥88 in females and ≥102 in males. Higher blood pressure: SBP ≥130 mmHg and/or DBP ≥85 mmHg or antihypertensive drug treatment. Higher FPG: FPG >100 mg/dl or antidiabetic drug treatment. Lower HDL cholesterol: HDL cholesterol <40 mg/dl in males and <50 mg/dl in females. Higher triglycerides: TGC >150 mg/dl)
  3. MetS metabolic syndrome; SBP systolic blood pressure; DBP diastolic blood pressure; HDL-C high density lipoprotein cholesterol; TGC triglycerides; FPG fasting plasma glucose; WC waist circumference; CAVI cardio-ankle vascular index; baPWV brachial-ankle pulse wave velocity
  4. * p < 0.05 in males, † p < 0.05 in females
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840